Exemestane (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Exemestane" in Italian language version.

refsWebsite

Global rank Italian rank

17nih.gov

4^th place

9^th place

10oadoi.org

799^th place

22^nd place

10doi.org

2^nd place

7^th place

doi.org

dx.doi.org

AU. Buzdar, JF. Robertson; W. Eiermann; JM. Nabholtz, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane., in Cancer, vol. 95, n. 9, Nov 2002, pp. 2006-16, DOI:10.1002/cncr.10908, PMID 12404296.
PE. Lønning, J. Geisler, Experience with exemestane in the treatment of early and advanced breast cancer., in Expert Opin Drug Metab Toxicol, vol. 4, n. 7, Jul 2008, pp. 987-97, DOI:10.1517/17425255.4.7.987, PMID 18624685.
JM. Nabholtz, MA. Mouret-Reynier; X. Durando; I. Van Praagh; S. Al-Sukhun; JP. Ferriere; P. Chollet, Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer., in Expert Opin Pharmacother, vol. 10, n. 9, Jun 2009, pp. 1435-47, DOI:10.1517/14656560902953738, PMID 19445563.
CJ. van de Velde, D. Rea; C. Seynaeve; H. Putter; A. Hasenburg; JM. Vannetzel; R. Paridaens; C. Markopoulos; Y. Hozumi; ET. Hille; DG. Kieback, Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial., in Lancet, vol. 377, n. 9762, Jan 2011, pp. 321-31, DOI:10.1016/S0140-6736(10)62312-4, PMID 21247627.
RC. Coombes, LS. Kilburn; CF. Snowdon; R. Paridaens; RE. Coleman; SE. Jones; J. Jassem; CJ. Van de Velde; T. Delozier; I. Alvarez; L. Del Mastro, Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial., in Lancet, vol. 369, n. 9561, Feb 2007, pp. 559-70, DOI:10.1016/S0140-6736(07)60200-1, PMID 17307102.
RC. Coombes, E. Hall; LJ. Gibson; R. Paridaens; J. Jassem; T. Delozier; SE. Jones; I. Alvarez; G. Bertelli; O. Ortmann; AS. Coates, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer., in N Engl J Med, vol. 350, n. 11, Mar 2004, pp. 1081-92, DOI:10.1056/NEJMoa040331, PMID 15014181.
RJ. Paridaens, LY. Dirix; LV. Beex; M. Nooij; DA. Cameron; T. Cufer; MJ. Piccart; J. Bogaerts; P. Therasse, Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group., in J Clin Oncol, vol. 26, n. 30, Oct 2008, pp. 4883-90, DOI:10.1200/JCO.2007.14.4659, PMID 18794551.
Y. Zhang, K. Simondsen; JM. Kolesar, Exemestane for primary prevention of breast cancer in postmenopausal women., in Am J Health Syst Pharm, vol. 69, n. 16, agosto 2012, pp. 1384-8, DOI:10.2146/ajhp110585, PMID 22855103.
PE. Goss, JN. Ingle; JE. Alés-Martínez; AM. Cheung; RT. Chlebowski; J. Wactawski-Wende; A. McTiernan; J. Robbins; KC. Johnson; LW. Martin; E. Winquist, Exemestane for breast-cancer prevention in postmenopausal women., in N Engl J Med, vol. 364, n. 25, Jun 2011, pp. 2381-91, DOI:10.1056/NEJMoa1103507, PMID 21639806.
ED. Deeks, LJ. Scott, Exemestane: a review of its use in postmenopausal women with breast cancer., in Drugs, vol. 69, n. 7, 2009, pp. 889-918, DOI:10.2165/00003495-200969070-00007, PMID 19441873.

nih.gov

ncbi.nlm.nih.gov

D. Giudici, G. Ornati; G. Briatico; F. Buzzetti; P. Lombardi; E. di Salle, 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor., in J Steroid Biochem, vol. 30, n. 1-6, 1988, pp. 391-4, PMID 3386266.
E. di Salle, G. Ornati; D. Giudici; M. Lassus; TR. Evans; RC. Coombes, Exemestane (FCE 24304), a new steroidal aromatase inhibitor., in J Steroid Biochem Mol Biol, vol. 43, n. 1-3, Sep 1992, pp. 137-43, PMID 1525055.
PE. Lønning, R. Paridaens; B. Thürlimann; G. Piscitelli; E. di Salle, Exemestane experience in breast cancer treatment., in J Steroid Biochem Mol Biol, vol. 61, n. 3-6, Apr 1997, pp. 151-5, PMID 9365185.
ER. Simpson, Sources of estrogen and their importance., in J Steroid Biochem Mol Biol, vol. 86, n. 3-5, Sep 2003, pp. 225-30, PMID 14623515.
AU. Buzdar, JF. Robertson; W. Eiermann; JM. Nabholtz, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane., in Cancer, vol. 95, n. 9, Nov 2002, pp. 2006-16, DOI:10.1002/cncr.10908, PMID 12404296.
AU. Buzdar, Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors., in Clin Cancer Res, vol. 9, 1 Pt 2, Jan 2003, pp. 468S-72S, PMID 12538502.
PE. Lønning, J. Geisler, Experience with exemestane in the treatment of early and advanced breast cancer., in Expert Opin Drug Metab Toxicol, vol. 4, n. 7, Jul 2008, pp. 987-97, DOI:10.1517/17425255.4.7.987, PMID 18624685.
JM. Nabholtz, MA. Mouret-Reynier; X. Durando; I. Van Praagh; S. Al-Sukhun; JP. Ferriere; P. Chollet, Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer., in Expert Opin Pharmacother, vol. 10, n. 9, Jun 2009, pp. 1435-47, DOI:10.1517/14656560902953738, PMID 19445563.
CJ. van de Velde, D. Rea; C. Seynaeve; H. Putter; A. Hasenburg; JM. Vannetzel; R. Paridaens; C. Markopoulos; Y. Hozumi; ET. Hille; DG. Kieback, Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial., in Lancet, vol. 377, n. 9762, Jan 2011, pp. 321-31, DOI:10.1016/S0140-6736(10)62312-4, PMID 21247627.
RC. Coombes, LS. Kilburn; CF. Snowdon; R. Paridaens; RE. Coleman; SE. Jones; J. Jassem; CJ. Van de Velde; T. Delozier; I. Alvarez; L. Del Mastro, Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial., in Lancet, vol. 369, n. 9561, Feb 2007, pp. 559-70, DOI:10.1016/S0140-6736(07)60200-1, PMID 17307102.
RC. Coombes, E. Hall; LJ. Gibson; R. Paridaens; J. Jassem; T. Delozier; SE. Jones; I. Alvarez; G. Bertelli; O. Ortmann; AS. Coates, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer., in N Engl J Med, vol. 350, n. 11, Mar 2004, pp. 1081-92, DOI:10.1056/NEJMoa040331, PMID 15014181.
DC. Johannessen, T. Engan; E. Di Salle; MG. Zurlo; J. Paolini; G. Ornati; G. Piscitelli; S. Kvinnsland; PE. Lonning, Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study., in Clin Cancer Res, vol. 3, n. 7, Jul 1997, pp. 1101-8, PMID 9815789.
B. Thürlimann, R. Paridaens; D. Serin; J. Bonneterre; H. Roché; R. Murray; E. di Salle; S. Lanzalone; MG. Zurlo; G. Piscitelli, Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group., in Eur J Cancer, vol. 33, n. 11, Oct 1997, pp. 1767-73, PMID 9470830.
RJ. Paridaens, LY. Dirix; LV. Beex; M. Nooij; DA. Cameron; T. Cufer; MJ. Piccart; J. Bogaerts; P. Therasse, Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group., in J Clin Oncol, vol. 26, n. 30, Oct 2008, pp. 4883-90, DOI:10.1200/JCO.2007.14.4659, PMID 18794551.
Y. Zhang, K. Simondsen; JM. Kolesar, Exemestane for primary prevention of breast cancer in postmenopausal women., in Am J Health Syst Pharm, vol. 69, n. 16, agosto 2012, pp. 1384-8, DOI:10.2146/ajhp110585, PMID 22855103.
PE. Goss, JN. Ingle; JE. Alés-Martínez; AM. Cheung; RT. Chlebowski; J. Wactawski-Wende; A. McTiernan; J. Robbins; KC. Johnson; LW. Martin; E. Winquist, Exemestane for breast-cancer prevention in postmenopausal women., in N Engl J Med, vol. 364, n. 25, Jun 2011, pp. 2381-91, DOI:10.1056/NEJMoa1103507, PMID 21639806.
ED. Deeks, LJ. Scott, Exemestane: a review of its use in postmenopausal women with breast cancer., in Drugs, vol. 69, n. 7, 2009, pp. 889-918, DOI:10.2165/00003495-200969070-00007, PMID 19441873.

oadoi.org

AU. Buzdar, JF. Robertson; W. Eiermann; JM. Nabholtz, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane., in Cancer, vol. 95, n. 9, Nov 2002, pp. 2006-16, DOI:10.1002/cncr.10908, PMID 12404296.
PE. Lønning, J. Geisler, Experience with exemestane in the treatment of early and advanced breast cancer., in Expert Opin Drug Metab Toxicol, vol. 4, n. 7, Jul 2008, pp. 987-97, DOI:10.1517/17425255.4.7.987, PMID 18624685.
JM. Nabholtz, MA. Mouret-Reynier; X. Durando; I. Van Praagh; S. Al-Sukhun; JP. Ferriere; P. Chollet, Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer., in Expert Opin Pharmacother, vol. 10, n. 9, Jun 2009, pp. 1435-47, DOI:10.1517/14656560902953738, PMID 19445563.
CJ. van de Velde, D. Rea; C. Seynaeve; H. Putter; A. Hasenburg; JM. Vannetzel; R. Paridaens; C. Markopoulos; Y. Hozumi; ET. Hille; DG. Kieback, Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial., in Lancet, vol. 377, n. 9762, Jan 2011, pp. 321-31, DOI:10.1016/S0140-6736(10)62312-4, PMID 21247627.
RC. Coombes, LS. Kilburn; CF. Snowdon; R. Paridaens; RE. Coleman; SE. Jones; J. Jassem; CJ. Van de Velde; T. Delozier; I. Alvarez; L. Del Mastro, Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial., in Lancet, vol. 369, n. 9561, Feb 2007, pp. 559-70, DOI:10.1016/S0140-6736(07)60200-1, PMID 17307102.
RC. Coombes, E. Hall; LJ. Gibson; R. Paridaens; J. Jassem; T. Delozier; SE. Jones; I. Alvarez; G. Bertelli; O. Ortmann; AS. Coates, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer., in N Engl J Med, vol. 350, n. 11, Mar 2004, pp. 1081-92, DOI:10.1056/NEJMoa040331, PMID 15014181.
RJ. Paridaens, LY. Dirix; LV. Beex; M. Nooij; DA. Cameron; T. Cufer; MJ. Piccart; J. Bogaerts; P. Therasse, Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group., in J Clin Oncol, vol. 26, n. 30, Oct 2008, pp. 4883-90, DOI:10.1200/JCO.2007.14.4659, PMID 18794551.
Y. Zhang, K. Simondsen; JM. Kolesar, Exemestane for primary prevention of breast cancer in postmenopausal women., in Am J Health Syst Pharm, vol. 69, n. 16, agosto 2012, pp. 1384-8, DOI:10.2146/ajhp110585, PMID 22855103.
PE. Goss, JN. Ingle; JE. Alés-Martínez; AM. Cheung; RT. Chlebowski; J. Wactawski-Wende; A. McTiernan; J. Robbins; KC. Johnson; LW. Martin; E. Winquist, Exemestane for breast-cancer prevention in postmenopausal women., in N Engl J Med, vol. 364, n. 25, Jun 2011, pp. 2381-91, DOI:10.1056/NEJMoa1103507, PMID 21639806.
ED. Deeks, LJ. Scott, Exemestane: a review of its use in postmenopausal women with breast cancer., in Drugs, vol. 69, n. 7, 2009, pp. 889-918, DOI:10.2165/00003495-200969070-00007, PMID 19441873.